IL297362A - Using surfactant protein d to treat viral infections - Google Patents
Using surfactant protein d to treat viral infectionsInfo
- Publication number
- IL297362A IL297362A IL297362A IL29736222A IL297362A IL 297362 A IL297362 A IL 297362A IL 297362 A IL297362 A IL 297362A IL 29736222 A IL29736222 A IL 29736222A IL 297362 A IL297362 A IL 297362A
- Authority
- IL
- Israel
- Prior art keywords
- rhsp
- pharmaceutical composition
- sars
- calcium
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013726P | 2020-04-22 | 2020-04-22 | |
| US202063072354P | 2020-08-31 | 2020-08-31 | |
| PCT/US2021/028207 WO2021216584A1 (en) | 2020-04-22 | 2021-04-20 | Use of surfactant protein d to treat viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297362A true IL297362A (en) | 2022-12-01 |
Family
ID=78270057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297362A IL297362A (en) | 2020-04-22 | 2021-04-20 | Using surfactant protein d to treat viral infections |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181697A1 (https=) |
| EP (1) | EP4138905A4 (https=) |
| JP (1) | JP7798791B2 (https=) |
| KR (1) | KR20230019089A (https=) |
| AU (1) | AU2021258178A1 (https=) |
| BR (1) | BR112022021423A2 (https=) |
| CA (1) | CA3180205A1 (https=) |
| IL (1) | IL297362A (https=) |
| MX (1) | MX2022013195A (https=) |
| WO (1) | WO2021216584A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023145916A1 (https=) * | 2022-01-31 | 2023-08-03 | ||
| WO2024097169A1 (en) * | 2022-11-01 | 2024-05-10 | National Jewish Health | Treatment of coronavirus infections with antimicrobial phospholipid compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933032B2 (en) * | 1998-10-20 | 2015-01-13 | Children's Hospital Medical Center | Surfactant protein D for the treatment of disorders associated with lung injury |
| US20030221199A1 (en) | 1998-10-20 | 2003-11-27 | Whitsett Jeffrey A. | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| US20120220531A1 (en) * | 2011-02-04 | 2012-08-30 | Cincinnati Children's Hospital Medical Center | Surfactant protein d for the treatment of disorders associated with lung injury |
| US20130216499A1 (en) * | 2012-02-17 | 2013-08-22 | Wenlin Huang | Compositions of recombinant human endostatin adenovirus injections and methods of production |
| NL2011626C2 (en) * | 2013-10-17 | 2015-04-20 | Stichting Tech Wetenschapp | Novel polypeptide and uses thereof. |
| JP7797098B2 (ja) * | 2018-03-29 | 2026-01-13 | エアウェイ・セラピューティクス・インコーポレイテッド | サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物 |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| KR102205028B1 (ko) * | 2020-03-22 | 2021-01-20 | (주)셀트리온 | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 |
| US11123329B1 (en) * | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| CN112481417B (zh) * | 2020-12-24 | 2022-05-27 | 山西大学 | 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒 |
-
2021
- 2021-04-20 AU AU2021258178A patent/AU2021258178A1/en active Pending
- 2021-04-20 BR BR112022021423A patent/BR112022021423A2/pt unknown
- 2021-04-20 IL IL297362A patent/IL297362A/en unknown
- 2021-04-20 CA CA3180205A patent/CA3180205A1/en active Pending
- 2021-04-20 WO PCT/US2021/028207 patent/WO2021216584A1/en not_active Ceased
- 2021-04-20 US US17/920,245 patent/US20230181697A1/en active Pending
- 2021-04-20 MX MX2022013195A patent/MX2022013195A/es unknown
- 2021-04-20 KR KR1020227040749A patent/KR20230019089A/ko not_active Withdrawn
- 2021-04-20 EP EP21792923.1A patent/EP4138905A4/en active Pending
- 2021-04-20 JP JP2022564443A patent/JP7798791B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230019089A (ko) | 2023-02-07 |
| JP2023523253A (ja) | 2023-06-02 |
| US20230181697A1 (en) | 2023-06-15 |
| EP4138905A4 (en) | 2024-04-17 |
| BR112022021423A2 (pt) | 2023-01-03 |
| JP7798791B2 (ja) | 2026-01-14 |
| AU2021258178A1 (en) | 2022-11-17 |
| CA3180205A1 (en) | 2021-10-28 |
| EP4138905A1 (en) | 2023-03-01 |
| MX2022013195A (es) | 2023-01-05 |
| WO2021216584A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL297362A (en) | Using surfactant protein d to treat viral infections | |
| IL264254A (en) | In vitro methods for increasing viability of immune-cells | |
| IL272361B1 (en) | Antibodies that bind active alpha-synuclein | |
| NZ582888A (en) | Charged lipoprotein complexes and their uses | |
| CN102772787A (zh) | 促胰岛素肽的稳定制剂 | |
| IL295167A (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| CN102834115B (zh) | 用于治疗流感的重组人cc10蛋白 | |
| IL297336A (en) | Methods for treating acute conditions using lipid binding protein-based complexes | |
| CN113201068A (zh) | 基因重组抗2019-nCoV和其它冠状病毒IgY及其小分子抗体以及应用 | |
| IL302066A (en) | Lipopeptide fusion inhibitors as sars-cov-2 antivirals | |
| Wu et al. | PEP-1-MsrA ameliorates inflammation and reduces atherosclerosis in apolipoprotein E deficient mice | |
| Imaizumi et al. | Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins | |
| Wang et al. | ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses | |
| IL301769A (en) | Methods for treating eye diseases using lipid binding protein-based complexes | |
| IL296960A (en) | Composition for prevention or treatment of hyperlipidemia comprising trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof and method using the same | |
| Sun et al. | Engineered MEVs for photoreceptor-targeted delivery of USP25 to alleviate diabetic retinopathy | |
| Almarhoun et al. | Overexpression of STARD3 attenuates oxidized LDL-induced oxidative stress and inflammation in retinal pigment epithelial cells | |
| US10086050B2 (en) | Treating infection | |
| Shin et al. | Multivalent display of ApoAI peptides on the surface of tobacco mosaic virus nanotubes improves cholesterol efflux | |
| Chen et al. | Novel perspectives on nanotechnological and biomedical implications of monotherapy or combination regimen of lactoferrin | |
| IL301088A (en) | Ribitol treatment | |
| IL268971B2 (en) | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof | |
| WO2021247756A1 (en) | Recombinant human cc10 protein for treatment of influenza, ebola, and coronavirus | |
| IL302126A (en) | Preparations that include tetrahydrocannabinol for the treatment of acute respiratory failure and/or acute respiratory distress syndrome | |
| TWI877962B (zh) | 載脂蛋白j拮抗肽用於製備促進脂質分解作用及減緩相關症候群之醫藥組成物的用途 |